4F-PHP

4F-PHP

4F-PHP is a synthetic stimulant of the cathinone and pyrrolidine chemical classes that produces typical cathinone-like stimulating and euphoric effects when administered. It is structurally related to compounds such as MDPV and is one of the successors to the designer drug α-PVP, also known as "flakka".

Chemistry

4F-PHP, also known as 1-(4-fluorophenyl)-2-(pyrrolidin-1-yl)hexan-1-one, is a synthetic cathinone. Cathinones are structurally similar to amphetamines, they contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα. Cathinones such as 4F-PHP are alpha-methylated phenethylamines (amphetamines) but also contain a ketone functional group at Rβ (a carbonyl group at the beta position of the amino butane side chain).

Pharmacology

The mechanism of action for 4F-PHP is believed to involve its functioning as a norepinephrine-dopamine reuptake inhibitor (NDRI), leading to an accumulation of these neurotransmitters in the brain and resulting in stimulating, euphoric, and empathogenic effects. However, the exact mechanisms of action are not fully understood, and further research is needed to fully understand the pharmacological profile of this substance.

Effects

The effects of 4F-PHP can vary greatly depending on the dose, individual physiology, and method of administration. Common effects reported by users include stimulation, euphoria, increased alertness and focus, and increased sociability. However, negative side effects can include anxiety, paranoia, insomnia, and potentially dangerous increases in heart rate and blood pressure.

Legal Status

The legal status of 4F-PHP varies by country and is subject to change. In many jurisdictions, it is classified as a controlled substance or is banned outright. It is always recommended to check the current legal status in your jurisdiction before obtaining or using this substance.

See Also

• Synthetic Cathinones
• Designer Drugs
• Stimulants
• Norepinephrine-Dopamine Reuptake Inhibitors

‎